Hydrocortisone

證據等級: L5

預測適應症: 10 個

Hydrocortisone: From Adrenal Insufficiency & Inflammatory Conditions to Alopecia Areata

One-Sentence Summary

Hydrocortisone is an endogenous glucocorticoid widely used as hormone replacement for adrenal insufficiency and as a topical or systemic anti-inflammatory agent across a broad range of inflammatory and allergic conditions.

The TxGNN model predicts it may be effective for Alopecia Areata, with 1 completed Phase 3 clinical trial and 20 publications currently supporting this direction — notably including a landmark randomised controlled trial published in JAMA Dermatology that directly evaluated hydrocortisone 1% cream in paediatric alopecia areata.

Quick Overview

Item	Content
Original Indication	Adrenal insufficiency; inflammatory, allergic, and autoimmune conditions (endogenous glucocorticoid)
Predicted New Indication	Alopecia Areata
TxGNN Prediction Score	99.97%
Evidence Level	L1
Australia Market Status	Not listed in ARTG (0 entries retrieved — manual verification recommended)
Number of ARTG Entries	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism of action data was not retrieved via the automated pipeline for this evidence pack. Based on established pharmacology, hydrocortisone is an endogenous glucocorticoid that acts primarily through the glucocorticoid receptor (GR). On binding GR, it suppresses pro-inflammatory transcription factors (NF-κB, AP-1), downregulates cytokine production, and broadly inhibits cellular immune responses — effects that are shared across the corticosteroid class.

Alopecia areata (AA) is an immune-mediated non-scarring hair loss disorder in which autoreactive CD8+ T cells breach the hair follicle’s immune privilege zone. Hydrocortisone’s GR-mediated immunosuppressive mechanism is directly relevant to this pathology: it suppresses CD8+ T-cell infiltration of the follicle, downregulates the IFN-γ/IL-15 signalling cascade that drives follicular immune privilege collapse, and reduces perifollicular inflammatory infiltration. Applied topically, it also attenuates the upstream JAK-STAT inflammatory drive. Among topical corticosteroids, hydrocortisone 1% is the preferred low-potency option for paediatric patients, balancing clinical effect against the lower risk of skin atrophy and hypothalamic-pituitary-adrenal (HPA) axis suppression compared with higher-potency agents such as clobetasol.

Clinical use of hydrocortisone in AA has a long history: case series from the 1950s and 1960s documented hair regrowth following intradermal and intracutaneous hydrocortisone injections. The 2014 JAMA Dermatology RCT (PMID 24226568) directly compared hydrocortisone 1% cream with clobetasol 0.05% cream in children with AA, providing Level 1 clinical evidence. This convergence of mechanistic plausibility, historical case evidence, and a completed Phase 3 RCT strongly supports the TxGNN prediction.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrolment	Key Findings
NCT01453686	Phase 3	Completed	41	Head-to-head RCT of clobetasol propionate 0.05% cream vs hydrocortisone 1% cream in children with alopecia areata; published as landmark trial in JAMA Dermatology (2014, PMID 24226568) — most directly relevant trial for this indication
NCT00484679	Phase 2	Completed	18	Assessed the impact of intralesional triamcinolone acetonide 10 mg/mL on adrenal function in alopecia areata patients; provides indirect safety context for corticosteroid class use in AA
NCT04343560	N/A	Completed	380	Examined effects of abnormal steroid metabolome on bone strength and body composition in adrenal adenoma patients; provides systemic safety context relevant to prolonged corticosteroid exposure
NCT06551818	N/A	Not Yet Recruiting	72	Four-arm dose-response study of topical hair growth products (including corticosteroid formulations) in mild-to-moderate androgenic alopecia; no results available yet

Literature Evidence

PMID	Year	Type	Journal	Key Findings
24226568	2014	RCT	JAMA Dermatology	Landmark RCT (n=41 children): hydrocortisone 1% cream vs clobetasol 0.05% cream for alopecia areata — primary efficacy evidence for this repurposing indication
38501938	2024	Clinical Study	Clinical and Experimental Dermatology	Retrospective single-centre analysis of topical corticosteroids under occlusion in children with severe AA (totalis/universalis); supports use of topical steroids in refractory paediatric cases
36718837	2023	Systematic Review	Journal of Cosmetic Dermatology	Systematic review and meta-analysis of fractional laser ± combination therapy in AA; contextualises topical corticosteroids as standard comparator within the AA treatment landscape
13368875	1956	Case Series	Medical Times	Early case series documenting hair regrowth in alopecia areata, partialis, and totalis following treatment with cortisone, hydrocortisone, and their analogues
13610145	1958	Case Report	Der Hautarzt	Case report documenting hair regrowth in alopecia areata and maligna after intracutaneous hydrocortisone injection — early direct-use evidence
5989830	1966	Case Series	Vestnik Dermatologii	Treatment of alopecia areata and total alopecia by intracutaneous hydrocortisone injections; historical clinical validation
14158891	1963	Case Report	Actas Dermo-Sifiliograficas	Intradermal hydrocortisone injection for alopecia areata — further historical evidence of direct drug use in this indication
15692503	2005	Case Report	JAAD	Four cases of congenital alopecia areata with 3–5 year follow-up; treatment included minoxidil 2% and topical corticosteroids, demonstrating treatment approach in very young patients
28516731	2017	Review	JEADV	Review of HPA axis hyperactivity hypothesis in alopecia areata; discusses cortisol and melanocyte-stimulating hormone (MSH) — provides neuroendocrine mechanistic context
39506493	2025	Exploratory Clinical Study	Journal of Cosmetic Dermatology	Explores chronic psychological stress effects on skin ageing; identifies cortisol and epinephrine as mediators in AA exacerbation, supporting the link between glucocorticoid signalling and AA pathogenesis

Australia Market Information

The automated ARTG query returned 0 entries for hydrocortisone, with a market status of “Not listed.” This is likely a limitation of the data retrieval methodology rather than a true reflection of Australian market availability, given that hydrocortisone-containing preparations (topical creams, tablets, injections) are well-established medicines in Australia.

Recommended action: Verify current ARTG registration status directly via the TGA ARTG Public Summary Search using “hydrocortisone” as the active ingredient. Multiple registered formulations are expected to be found, including topical 1% and 0.5% creams relevant to this indication.

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for complete safety information.

Important note for prescribers: Formal safety data was not retrieved via the automated pipeline. As a topical corticosteroid, hydrocortisone carries class-specific considerations of particular relevance to alopecia areata use, including: risk of HPA axis suppression with extensive or prolonged application (especially in children); local skin atrophy with long-term use; and avoidance of ocular contact. A full PI review is essential before clinical use, particularly for paediatric patients.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: A completed Phase 3 RCT directly evaluated hydrocortisone 1% cream in paediatric alopecia areata (JAMA Dermatology, 2014), supported by over 60 years of historical clinical case evidence and a mechanistically sound glucocorticoid receptor–mediated pathway. The TxGNN prediction score of 99.97% is consistent with this well-evidenced indication.

To proceed, the following is needed:

ARTG verification: Manual search of the TGA ARTG database to identify currently registered hydrocortisone topical preparations and confirm which are available in formulations suitable for scalp/dermal use in alopecia areata
PI review: Obtain and review TGA-approved Product Information for registered hydrocortisone topical products to confirm dosage forms, approved concentrations, and any existing dermatological indications
Paediatric safety monitoring plan: Define monitoring parameters for HPA axis suppression (e.g., morning cortisol, stimulation test if clinically indicated) for use in children with widespread or prolonged application
Regulatory pathway clarification: Determine whether this use constitutes approved, off-label, or indication-extension use under Australian prescribing regulations; if indication extension is pursued, outline a TGA application pathway
Comparative effectiveness assessment: Review whether higher-potency topical corticosteroids (e.g., clobetasol) or newer agents (e.g., JAK inhibitors — baricitinib is TGA-approved for AA) represent a superior standard of care, to position hydrocortisone 1% appropriately within the treatment algorithm, particularly for mild and paediatric cases
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.